                               SEQUENCE LISTING

<110> THE SCHEPENS EYE RESEARCH INSTITUTE, INC.
 
<120> A THERAPEUTIC APPROACH FOR TREATING NON-INFECTIOUS OCULAR 
      IMMUNOINFLAMMATORY DISORDERS

<130> 036770-579001WO

<140> PCT/US2020/035222
<141> 2020-05-29

<150> 62/879,839
<151> 2019-07-29

<150> 62/854,575
<151> 2019-05-30

<160> 4     

<170> PatentIn version 3.5

<210> 1
<211> 407
<212> PRT
<213> Homo sapiens

<400> 1
Met Asp Asn Val Leu Pro Val Asp Ser Asp Leu Ser Pro Asn Ile Ser 
1               5                   10                  15      


Thr Asn Thr Ser Glu Pro Asn Gln Phe Val Gln Pro Ala Trp Gln Ile 
            20                  25                  30          


Val Leu Trp Ala Ala Ala Tyr Thr Val Ile Val Val Thr Ser Val Val 
        35                  40                  45              


Gly Asn Val Val Val Met Trp Ile Ile Leu Ala His Lys Arg Met Arg 
    50                  55                  60                  


Thr Val Thr Asn Tyr Phe Leu Val Asn Leu Ala Phe Ala Glu Ala Ser 
65                  70                  75                  80  


Met Ala Ala Phe Asn Thr Val Val Asn Phe Thr Tyr Ala Val His Asn 
                85                  90                  95      


Glu Trp Tyr Tyr Gly Leu Phe Tyr Cys Lys Phe His Asn Phe Phe Pro 
            100                 105                 110         


Ile Ala Ala Val Phe Ala Ser Ile Tyr Ser Met Thr Ala Val Ala Phe 
        115                 120                 125             


Asp Arg Tyr Met Ala Ile Ile His Pro Leu Gln Pro Arg Leu Ser Ala 
    130                 135                 140                 


Thr Ala Thr Lys Val Val Ile Cys Val Ile Trp Val Leu Ala Leu Leu 
145                 150                 155                 160 


Leu Ala Phe Pro Gln Gly Tyr Tyr Ser Thr Thr Glu Thr Met Pro Ser 
                165                 170                 175     


Arg Val Val Cys Met Ile Glu Trp Pro Glu His Pro Asn Lys Ile Tyr 
            180                 185                 190         


Glu Lys Val Tyr His Ile Cys Val Thr Val Leu Ile Tyr Phe Leu Pro 
        195                 200                 205             


Leu Leu Val Ile Gly Tyr Ala Tyr Thr Val Val Gly Ile Thr Leu Trp 
    210                 215                 220                 


Ala Ser Glu Ile Pro Gly Asp Ser Ser Asp Arg Tyr His Glu Gln Val 
225                 230                 235                 240 


Ser Ala Lys Arg Lys Val Val Lys Met Met Ile Val Val Val Cys Thr 
                245                 250                 255     


Phe Ala Ile Cys Trp Leu Pro Phe His Ile Phe Phe Leu Leu Pro Tyr 
            260                 265                 270         


Ile Asn Pro Asp Leu Tyr Leu Lys Lys Phe Ile Gln Gln Val Tyr Leu 
        275                 280                 285             


Ala Ile Met Trp Leu Ala Met Ser Ser Thr Met Tyr Asn Pro Ile Ile 
    290                 295                 300                 


Tyr Cys Cys Leu Asn Asp Arg Phe Arg Leu Gly Phe Lys His Ala Phe 
305                 310                 315                 320 


Arg Cys Cys Pro Phe Ile Ser Ala Gly Asp Tyr Glu Gly Leu Glu Met 
                325                 330                 335     


Lys Ser Thr Arg Tyr Leu Gln Thr Gln Gly Ser Val Tyr Lys Val Ser 
            340                 345                 350         


Arg Leu Glu Thr Thr Ile Ser Thr Val Val Gly Ala His Glu Glu Glu 
        355                 360                 365             


Pro Glu Asp Gly Pro Lys Ala Thr Pro Ser Ser Leu Asp Leu Thr Ser 
    370                 375                 380                 


Asn Cys Ser Ser Arg Ser Asp Ser Lys Thr Met Thr Glu Ser Phe Ser 
385                 390                 395                 400 


Phe Ser Ser Asn Val Leu Ser 
                405         


<210> 2
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 2
Arg Pro Lys Pro Gln Gln Trp Phe Trp Leu Leu 
1               5                   10      


<210> 3
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 3
Leu Asp Gln Trp Phe Gly 
1               5       


<210> 4
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 4
Gln Trp Phe Gly Leu Met 
1               5       


